Neuromyelitis Optica Spectrum Disorder Mechanisms and Clinical Insights

Neuromyelitis optica spectrum disorder (NMOSD) is a severe, antibody-mediated inflammatory disease of the central nervous system, primarily affecting the optic nerves and spinal cord. The hallmark of NMOSD is the presence of immunoglobulin G autoantibodies against aquaporin-4 (AQP4), a water channel densely expressed on astrocytic endfeet. Binding of these antibodies triggers complement-dependent cytotoxicity, astrocyte loss and secondary demyelination. In recent years, a subset of patients negative for AQP4-IgG has been shown to harbour antibodies against myelin oligodendrocyte glycoprotein (MOG), indicating distinct immunopathological mechanisms. Clinically, NMOSD presents with episodes of optic neuritis, longitudinally extensive transverse myelitis and area postrema syndrome, often leading to significant visual and motor disability if not promptly treated. Magnetic resonance imaging typically reveals longitudinal spinal lesions and periependymal brain abnormalities, while serological testing for AQP4-IgG and MOG-IgG has become a cornerstone of diagnosis. Advances in targeted therapies, including B-cell depletion and complement inhibition, have substantially reduced relapse rates. Emerging research explores biomarkers for seronegative patients, the role of blood–brain barrier disruption in lesion formation and the genetic underpinnings of individual susceptibility. Improved diagnostic criteria and the advent of precision immunotherapies underscore the global impact of NMOSD research in reducing morbidity and informing management strategies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neuromyelitis Optica Spectrum Disorder Mechanisms and Clinical Insights publication trend

The graph below shows the total number of articles in neuromyelitis optica spectrum disorder mechanisms and clinical insights across all publications each year (not limited to Nature Index journals).

Technical terms

Aquaporin-4 antibodies: Autoantibodies targeting the water channel protein aquaporin-4 on astrocytes, central to NMOSD pathogenesis.

Longitudinally extensive transverse myelitis (LETM): A spinal cord lesion extending across three or more vertebral segments, characteristic of NMOSD.

Area postrema syndrome: A clinical presentation of intractable nausea, vomiting or hiccups due to lesions in the area postrema of the brainstem, recognised as a core NMOSD feature.

Myelin oligodendrocyte glycoprotein (MOG): A myelin protein that may be targeted by autoantibodies in a subset of NMOSD patients distinct from AQP4-seropositive cases.

References

1. Paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian dysgerminoma: a case report and literature review. Frontiers in Immunology (2024).
2. NMOSD—Diagnostic Dilemmas Leading towards Final Diagnosis. Brain Sciences (2022).
3. Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies. Frontiers in Neurology (2020).